Precision Medicine Stocks List Ranked for 2024 |

Symbol	Grade	Name	% Change
RLAY	F	Relay Therapeutics, Inc.	-0.43
BIOR	F	Biora Therapeutics, Inc.	0.62
POAI	F	Predictive Oncology Inc.	5.58
INMB	F	INmune Bio Inc.	4.39
RPTX	F	Repare Therapeutics Inc.	4.58
NTLA	F	Intellia Therapeutics, Inc.	5.18
ORIC	F	Oric Pharmaceuticals, Inc.	4.35
IDYA	F	IDEAYA Biosciences, Inc.	4.15
STOK	F	Stoke Therapeutics, Inc.	-0.35
AVTX	D	Avalo Therapeutics, Inc.	-11.47

Symbol	Grade	Name	Weight
CNCR	F	Loncar Cancer Immunotherapy ETF	2.23
LRNZ	A	TrueMark Technology, AI & Deep Learning ETF	0.8
CANC	D	Tema Oncology ETF	0.69
ARKG	F	ARK Genomic Revolution Multi-Sector ETF	0.64
BBC	F	Virtus LifeSci Biotech Clinical Trials ETF	0.57

Compare ETFs

Date	Stock	Title
Nov 20	STOK	Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Nov 20	RLAY	Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
Nov 19	RLAY	Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
Nov 19	NTLA	Intellia Therapeutics Announces Promising CRISPR Therapy Results
Nov 19	NTLA	ReCode to secure funds for cystic fibrosis gene correction treatments
Nov 19	NTLA	Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
Nov 19	NTLA	Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Nov 18	NTLA	Intellia’s gene editing therapy shows early potential in rare heart condition
Nov 18	NTLA	CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
Nov 18	IDYA	IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
Nov 16	NTLA	Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
Nov 15	IDYA	Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It

Precision Medicine: Precision medicine (PM) is a medical model that proposes the customization of healthcare, with medical decisions, treatments, practices, or products being tailored to the individual patient, instead of a one‐drug‐fits‐all model. In precision medicine, diagnostic testing is often employed for selecting appropriate and optimal therapies based on the context of a patient’s genetic content or other molecular or cellular analysis. Tools employed in precision medicine can include molecular diagnostics, imaging, and analytics.